SCHEMBL2947006

SCHEMBL2947006

COc1cccc(C=O)c1Cc1c(C(=O)OC(C)(C)C)c(OC)cc2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC37A4 O43826 7/20 0.48
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
LCK P06239 1/20 0.38
GLA P06280 1/20 0.38
THRB P10828 1/20 0.38
LIMK1 P53667 1/20 0.38
LIMK2 P53671 1/20 0.38
ELANE P08246 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
ERN1 O75460 4/20 0.34
TLR2 O60603 1/20 0.34
TLR1 Q15399 1/20 0.34
TLR6 Q9Y2C9 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955820 0.86 SLC37A4 (0.46) SLC37A4MAPTALDH1A1ELANEMTNR1A
SCHEMBL4453653 0.85 SLC37A4 (0.40) SLC37A4MAPTALDH1A1LCKGLA
Anthraquinone SCHEMBL2946623 0.81 SLC37A4 (0.45) SLC37A4MAPTALDH1A1LCKGLA
SCHEMBL2955955 0.81 SLC37A4 (0.45) SLC37A4MAPTALDH1A1LCKGLA
SCHEMBL2948794 0.81 SLC37A4 (0.44) SLC37A4ALDH1A1THRBMTNR1AMTNR1B
Anthraquinone SCHEMBL2948902 0.79 SLC37A4 (0.48) SLC37A4ELANEMEN1KMT2A
SCHEMBL2946624 0.76 SLC37A4 (0.48) SLC37A4ELANEMEN1KMT2A
SCHEMBL2957671 0.76 MAPT (0.44) SLC37A4MAPTALDH1A1LCKGLA
SCHEMBL2959701 0.76 SLC37A4 (0.38) SLC37A4
SCHEMBL2956199 0.74 SLC37A4 (0.36) SLC37A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763740-B2 Method for the production of mumbaistatin derivatives SANOFI-AVENTIS (FR) 2010-07-27 US disclosed
US-20090156836-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES SANOFI-AVENTIS (FR) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156836-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES MMAB, MLYCD, HMBS SLC37A4 4052/4885MAPT 4145/4885ALDH1A1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.